Eritoran

DB04933InvestigationalSmall molecule

Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

Mechanism: Eritoran is a toll-like receptor 4 inhibitor.
Curator reviewed
Primary indication: Investigated for use/treatment in sepsis and septicemia.Curator reviewed
Formula / weight: C₆₆H₁₂₆N₂O₁₉P₂ · 1313.6562 g/mol (avg)
Code names: E5564

Resolves to

Compound

UNII551541VI0YCAS185955-34-4ChEMBLCHEMBL501259ChEBI68609PubChem6912404KEGGD04043

Structure

InChIKeyBPSMYQFMCXXNPC-MFCPCZTFSA-NSMILES

CCCCCCCCCCCC(=O)CC(=O)N[C@H]1[C@@H](OP(O)(O)=O)O[C@H](CO[C@@H]2O[C@H](COC)[C@@H](OP(O)(O)=O)[C@H](OCC[C@@H](CCCCCCC)OC)[C@H]2NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](O)[C@@H]1OCCCCCCCCCC

Targets

O00206TLR4

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eritoran, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account